Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

KaiNETIC-3

Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 1270

NCT07284979

ArmPopulationDoseWeeksEstimandWeight change
Ribupatide: Dose 1Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 2Obesity or overweightn/rn/rn/rn/r
SemaglutideObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r